Vivitrol's Opioid Abuse Claim Will Likely Need Monitoring and Support Services
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee voted in favor of expanding the indication for Alkermes' alcoholism treatment by lopsided margins, with the caveat that monitoring and support must be provided to patients.
You may also be interested in...
Can Alkermes' Vivitrol Live Up To Commercial Potential In Opioid Dependence?
Company does not plan to compete against market-leading Suboxone, and will initially target the newly addicted, such as young adults, and certain professionals who can't take available treatments.
Can Alkermes' Vivitrol Live Up To Commercial Potential In Opioid Dependence?
Company does not plan to compete against market-leading Suboxone, and will initially target the newly addicted, such as young adults, and certain professionals who can't take available treatments.